- Home
- RSVR vs ATXS Comparison
RSVR vs ATXS Comparison
Compare RSVR & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSVR
- ATXS
- Stock Information
- Founded
- RSVR 2007
- ATXS 2008
- Country
- RSVR United States
- ATXS United States
- Employees
- RSVR N/A
- ATXS N/A
- Industry
- RSVR Movies/Entertainment
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- RSVR Consumer Discretionary
- ATXS Health Care
- Exchange
- RSVR Nasdaq
- ATXS Nasdaq
- Market Cap
- RSVR 562.3M
- ATXS 584.1M
- IPO Year
- RSVR N/A
- ATXS 2015
- Fundamental
- Price
- RSVR $9.28
- ATXS $9.55
- Analyst Decision
- RSVR Strong Buy
- ATXS Strong Buy
- Analyst Count
- RSVR 1
- ATXS 5
- Target Price
- RSVR $12.50
- ATXS $28.00
- AVG Volume (30 Days)
- RSVR 36.3K
- ATXS 340.4K
- Earning Date
- RSVR 02-05-2025
- ATXS 11-13-2024
- Dividend Yield
- RSVR N/A
- ATXS N/A
- EPS Growth
- RSVR N/A
- ATXS N/A
- EPS
- RSVR N/A
- ATXS N/A
- Revenue
- RSVR $149,606,040.00
- ATXS N/A
- Revenue This Year
- RSVR $7.18
- ATXS N/A
- Revenue Next Year
- RSVR $7.33
- ATXS N/A
- P/E Ratio
- RSVR N/A
- ATXS N/A
- Revenue Growth
- RSVR 10.84
- ATXS N/A
- 52 Week Low
- RSVR $5.95
- ATXS $5.88
- 52 Week High
- RSVR $9.83
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- RSVR 54.05
- ATXS 41.21
- Support Level
- RSVR $8.99
- ATXS $9.40
- Resistance Level
- RSVR $9.59
- ATXS $9.99
- Average True Range (ATR)
- RSVR 0.29
- ATXS 0.58
- MACD
- RSVR -0.05
- ATXS -0.01
- Stochastic Oscillator
- RSVR 34.91
- ATXS 9.32
About RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. The company's segment includes Music Publishing; Recorded Music and others. It generates the maximum of its revenue from the Music Publishing segment.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.